Floatz logo

Therapeutic Asset Ratings

623 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Tucatinib
Breast Cancer
MedSIRP3B (58)
Utidelone
Breast Cancer
Beijing Biostar Pharmaceuticals Co., Ltd.P3B (58)
Bendamustine
Breast Cancer
University of ZurichP2B (58)
Dasatinib
Breast Cancer
National Cancer Institute (NCI)P2B (58)
Gm-Csf
Breast Cancer
Washington University School of MedicineP2B (58)
Ruxolitinib
Breast Cancer
Baylor Research InstituteP2B (58)
TIL
Breast Cancer
Essen BiotechP2B (58)
MAGNESIUM METALLICUM
Breast Cancer
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyP2/3B (58)
Pentoxifylline
Breast Cancer
Tanta UniversityP2/3B (58)
IBUPROFEN
Breast Cancer
Aga Khan UniversityP4B (57)
Cediranib
Breast Cancer
M.D. Anderson Cancer CenterP3B (57)
Lansoprazole
Breast Cancer
The Christie NHS Foundation TrustP3B (57)
SIMVASTATIN
Breast Cancer
Emory UniversityP3B (57)
Polyiclc
Breast Cancer
University of Southern CaliforniaP2B (57)
Obinutuzumab
Breast Cancer
Japan Breast Cancer Research GroupP2/3B (57)
DICLOFENAC
Breast Cancer
The Second Affiliated Hospital of Hainan Medical UniversityP4B (56)
Gentamycin
Breast Cancer
Memorial Sloan Kettering Cancer CenterP4B (56)
PROPRANOLOL
Breast Cancer
Chang-Ik YoonP4B (56)
S-Ketamine
Breast Cancer
Chinese PLA General HospitalP4B (56)
Vancomycin
Breast Cancer
Jewish General HospitalP4B (56)
ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166
Breast Cancer
Fudan UniversityP2B (56)
Azacitidine
Breast Cancer
National University Hospital, SingaporeP2B (56)
Bazedoxifene
Breast Cancer
University of Kansas Medical CenterP2B (56)
Casodex
Breast Cancer
Icahn School of Medicine at Mount SinaiP2B (56)
Patritumab Deruxtecan
Breast Cancer
Merck Sharp & Dohme LLCP2B (56)
Showing 126 to 150 of 623 assets
PreviousPage 6 of 25Next